Beam Therapeutics Inc.·4

Apr 2, 5:22 PM ET

Cavanagh Bethany J 4

Research Summary

AI-generated summary

Updated

Beam Therapeutics SVP Bethany Cavanagh Receives 20,000 RSUs

What Happened Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics (BEAM), received a grant of 20,000 restricted stock units (RSUs) on March 31, 2026. The RSUs were granted at a $0.00 per-unit price (no immediate cash value reported). This transaction is an award/grant (not a market purchase or sale).

Key Details

  • Transaction date and type: 2026-03-31 — Grant/Award of 20,000 RSUs; reported per-unit price $0.00 (total reported value $0).
  • Shares owned after transaction: Not specified in the supplied filing excerpt.
  • Footnote: F1 — Each RSU represents the contingent right to one share of BEAM common stock; RSUs vest in four substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service.
  • Filing timeliness: Form filed 2026-04-02; this appears to be timely (within the typical two-business-day Form 4 reporting window).

Context RSU grants are a form of equity compensation that convert to actual company shares only as they vest; they do not require an upfront cash outlay. Such awards are common for executive pay and do not by themselves indicate buying or selling intent in the open market.